Impact of MDM2, TP53 and P14ARF polymorphisms on endometrial cancer risk and onset

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The aim of this study was to determine the joint effect of single nucleotide polymorphisms (SNPs) of MDM2, TP53, and CDKN2A (P14ARF) genes on the onset and course of endometrial cancer (EC) in postmenopausal women. Materials and Methods: The study group consisted of 144 EC women and 50 non-cancer controls. MDM2 rs22279744, TP53 rs1042522, and P14ARF rs3088440, rs3731217, and rs3731245 SNPs were analysed. Results: The double-SNP combinations T-C, T-T, or T-G in MDM2 SNP 309 and P14ARF polymorphisms decreased EC risk. The triple-SNP combinations T-C-T, T-C-G, or T-T-G in MDM2 SNP and two P14ARF polymorphisms decreased EC risk. The multiple-SNP combination T-C-T-G in MDM2 and three P14ARF polymorphisms decreased EC risk. The G-Arg-C-T-G carriers were at increased EC risk, while the T-Arg-C-T-G carriers were at decreased EC risk. Conclusion: MDM2 SNP309 plays a role in EC onset in postmenopausal women.

Cite

CITATION STYLE

APA

Wujcicka, W., Zając, A., & Stachowiak, G. (2019). Impact of MDM2, TP53 and P14ARF polymorphisms on endometrial cancer risk and onset. In Vivo, 33(3), 917–924. https://doi.org/10.21873/invivo.11559

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free